Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2017 | What is induction therapy for autologous stem cell transplanation?

Michele Cavo • 21 Apr 2017
COMy 2017
Multiple Myeloma Lenalidomide

Michele Cavo, MD, from the Bologna University School of Medicine, Bologna, Italy, discusses current guidelines for induction therapy for autologous stem cell transplantation at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. The International Myeloma Working Group and the ESMO guidelines recommend a three-drug regimen including a proteasome inhibitor as the standard of care induction therapy for patients undergoing autologous stem cell transplantation. Lenalidomide is recommended as the standard of care maintenance therapy for this treatment.

More from Michele Cavo

1:37
Treatment options for patients with triple-class refractory myeloma: the value of immunotherapy
Michele Cavo • 28 Sep 2023
1:36
The importance of MRD as a prognostic tool in multiple myeloma
Michele Cavo • 28 Sep 2023
1:24
CD38-targeting triplets for myeloma
Michele Cavo • 17 May 2022
1:43
How has the role of transplant changed with the introduction of CAR-T therapy?
Michele Cavo • 17 May 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals